The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study
The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.
Conditions:
🦠 Takotsubo Cardiomyopathy
🗓️ Study Start (Actual) 1 February 2019
🗓️ Primary Completion (Estimated) February 2029
✅ Study Completion (Estimated) February 2029
👥 Enrollment (Estimated) 1000
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Los Angeles, California, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Have received a diagnosis of Takotsubo from their physician and consent to enroll
    • * Submit full medical records needed for Takotsubo adjudication

    Exclusion Criteria:

    • * Younger than 18 years
    • * Unable to provide informed consent
    • * Unable to provide the necessary documentation needed for screening purposes
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 6 March 2019
  • First Submitted that Met QC Criteria 8 April 2019
  • First Posted 10 April 2019

Study Record Updates

  • Last Update Submitted that Met QC Criteria 6 September 2023
  • Last Update Posted 8 September 2023
  • Last Verified September 2023